Urinary Biomarkers of OI Pathobiology

NCT ID: NCT02531087

Last Updated: 2025-12-01

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Total Enrollment: 25 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2015-08-17
• Study Completion Date: 2026-08-31

Brief Summary

Osteogenesis imperfecta (OI) is a rare inherited disorder that causes bones to break easily. Individuals with osteogenesis imperfecta break bones often and may have other problems, including hearing loss, dental problems, pain and difficulty getting around. Before the genetic cause of OI was known, OI was classified into four types. Each type was based upon the symptoms and severity of OI. In most people with OI, the cause is a change in one of the genes that makes a protein called type 1 collagen. Some doctors now classify OI both on how severe it is as well as which gene is causing OI. When people classify OI this way, there are more than 10 types of OI. The current laboratory testing to determine OI subtype involves the collection of blood and/or skin cells.

Detailed Description

Osteogenesis Imperfecta (OI) is a rare disorder that causes bones to break easily. People with OI may have broken bones with little or no trauma, dentinogenesis imperfecta (DI), and, in adult years, hearing loss. It is seen in both genders and all races. OI can range from very severe to very mild. Individuals with the most severe type of OI may die at birth. People with severe OI who survive may have bowed arms and legs, very short stature and be unable to walk. People with the mildest form of OI may only break bones occasionally and have normal height and lifespan. Breaks can occur in any bone, but are most common in the arms and legs. People with OI also often have problems with the spine. The spine problems include compression fractures and scoliosis (a curvature of the spine). DI is characterized by grey or brown teeth that may chip and wear down and break easily. In addition to weak teeth, the teeth in the upper jaw may not match up with the teeth in the lower jaw.

Before the genetic cause of OI was known, OI was classified into four types. Each type was based upon the symptoms and severity of OI. In most people with OI, the cause is a change in one of the genes that makes a protein called type 1 collagen. In the past decade, it was discovered that in about 5% of people with OI it is in another gene. Some doctors now classify OI both on how severe it is as well as which gene is causing OI. When people classify OI this way, there are more than 10 types of OI. The current laboratory testing to determine OI subtype involves the collection of blood and/or skin cells.

Conditions

Osteogenesis Imperfecta

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Individuals with OI

Individuals with OI with confirmed specific genetic mutations

No interventions assigned to this group

Controls/Unaffected

Individuals who do not have OI and who are not related to an individual with OI

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• To be able to participate, you must:

Be enrolled in The Longitudinal Study of OI (NTC #02432625) and have one of the following genetic mutations:

• glycine substitution mutations in COL1A1 or COL1A2
• haploinsufficient mutation in COL1A1 or COL1A2
• mutations in CRTAP, PPIB, or LEPRE1
• mutations in FKBP10 or SERPINH1
• mutations in (SERPINF1, WNT1, or IFITM5)
• dominant negative glycine substitutions and haploinsufficient mutations in COL1A1, and COL1A2

If you are serving as a control, you must not be related to an individual with OI.

Exclusion Criteria

• You cannot participate if:
• You are unable to comply with the sample collection schedule.
• You are related to one of the OI subjects and would like to serve as a control subject.
• You have vertebral instrumentation or spinal deformities where we cannot assess lumbar spine aBMD.
• You have a history of recent fracture (< 3 months).
• You have serum creatinine above 1x upper limits of normal.
• You have abnormal kidney function.
• You are using Minoxidil.
• You are unable to provide a urine sample readily.

• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Shriners Hospitals for Children

OTHER

Sponsor Role: collaborator

University of Nebraska

OTHER

Sponsor Role: collaborator

University of Washington

OTHER

Sponsor Role: collaborator

Baylor College of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Brendan Lee

Professor and Chairman

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Vernon Reid Sutton, M.D.

Role: PRINCIPAL_INVESTIGATOR

Baylor College of Medicine

Frank Rauch, M.D.

Role: PRINCIPAL_INVESTIGATOR

Shriners Hospital for Children

David Eyre, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

University of Washington

Locations

University of California Los Angeles

Los Angeles, California, United States

University of Nebraska Medical Center

Omaha, Nebraska, United States

Hospital for Special Surgery

New York, New York, United States

Oregon Health Science University

Portland, Oregon, United States

Baylor College of Medicine

Houston, Texas, United States

Shriners Hospital for Children

Milwauke, Wisconsin, United States

Shriners Hospital for Children

Montreal, Quebec, Canada

Countries

United States; Canada

Other Identifiers

37358

Identifier Type: -

Identifier Source: org_study_id